Loading…
Sensus Healthcare, Inc. is projected to rise to $3.77 by 2027, a +20% move from its current price of $3.13. SRTS is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 5/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| May 29 | $3.03 | $3.13 | $3.23 | -0.03% |
| May 30 | $2.99 | $3.13 | $3.28 | -0.05% |
| May 31 | $2.95 | $3.13 | $3.31 | -0.08% |
| Jun 1 | $2.93 | $3.13 | $3.34 | -0.11% |
| Jun 2 | $2.90 | $3.13 | $3.36 | -0.14% |
| Jun 3 | $2.88 | $3.12 | $3.39 | -0.16% |
| Jun 4 | $2.86 | $3.12 | $3.41 | -0.19% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $2.86 | $3.12 | $3.41 | -0.19% |
| Week 2 | $2.76 | $3.12 | $3.53 | -0.38% |
| Week 3 | $2.68 | $3.11 | $3.62 | -0.57% |
| Week 4 | $2.61 | $3.11 | $3.70 | -0.76% |
| Week 5 | $2.55 | $3.10 | $3.77 | -0.95% |
| Week 6 | $2.50 | $3.09 | $3.83 | -1.13% |
| Week 7 | $2.45 | $3.09 | $3.89 | -1.32% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Sensus Healthcare, Inc. operates as a medical device company that manufactures and sells radiation therapy devices to healthcare providers worldwide. The company uses superficial radiation therapy, a low-energy X-ray technology in its portfolio of treatment devices.
It offers SRT-100, a photon X-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating non-melanoma skin cancers, including basal cell and squamous cell skin cancers, as well as other skin conditions, such as keloids. It also markets SRT-100 Vision, which provides the user with a superficial radiation therapy-tailored treatment planning application that integrates an embedded high frequency ultrasound imaging module, volumetric tumor analysis, beam margins planning, and dosimetry parameters. The company also provides SRT-100 +; Sentinel service program, which offers its customers protection for their systems; and Transdermal Infusion system, a biophysical alternative to infuse high weight molecule modalities into the dermis for medical and aesthetic purposes without the use of needles.
In addition, it sells disposable lead shielding replacements; and disposable radiation safety items, such as aprons and eye shields, ultrasound probe film, and disposable applicator tips to treat various sized lesions and various areas of the body. Further, the company distributes laser devices, such as applications for hair removal, vascular lesions, acne treatment, skin toning, and skin rejuvenation, as well as epidermal pigment removal for spots, freckles, and tattoos, as well as provide operational healthcare services for dermatology clinics. It markets its products primarily to private dermatology practices, and radiation oncologists in both private and hospital settings.
The company was incorporated in 2010 and is based in Boca Raton, Florida.
Sensus Healthcare, Inc. (SRTS) is a Healthcare stock with a current price of $3.19 per share and a market capitalization of $52.51M. It holds a rank of 4570 in market capitalization. The company operates in the medical device sector, focusing on superficial radiation therapy devices such as the SRT-100 family and SRT-100 Vision.
A major floor 31.1% below — a decisive break under it would weaken the trend.
Price is testing support right now (1.6% away) — a key level to hold.
The nearest ceiling, 43.5% above — a clean break opens room to run.
A major ceiling 69.3% above — clearing it would confirm fresh momentum.
Key SRTS support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of SRTS market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $3.21 | Sell | $3.22 | Sell |
| MA 10 | $3.36 | Sell | $3.33 | Sell |
| MA 20 | $3.57 | Sell | $3.52 | Sell |
| MA 50 | $3.91 | Sell | $3.82 | Sell |
| MA 100 | $4.23 | Sell | $3.98 | Sell |
| MA 200 | $3.88 | Sell | $4.15 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 32.62 | Neutral |
| Stoch RSI (14) | 29.96 | Neutral |
| CCI (20) | -95.80 | Neutral |
| Williams %R (14) | -95.15 | Info |
| MACD (12,26,9) | -0.03 | Sell |
| ROC (12) | 1.62 | Buy |
| Bollinger %B (20,2) | 0.18 | Neutral |
| Stochastic %K (14) | 4.85 | Buy |
| TRIX (15) | -0.74 | Sell |
| Awesome (5,34) | -0.62 | Sell |
| Ultimate (7,14,28) | 13.36 | Buy |
| Momentum (10) | -0.24 | Sell |
| Aroon Osc (25) | -4.00 | Sell |
| Hull MA (9) | 3.11 | Buy |
| ADX (14) | 22.62 | Sell |
| ATR (14) | 0.11 | Info |
The 30-day technical picture is neutral, with RSI14 at 30. The stock’s near-term momentum sits between the key moving averages, with SMA50 at $3.94 and SMA200 at $3.89. Support is noted at $3.08 and resistance at $4.49. The 30-day price range spans from $2.54 to $4.01, highlighting a modest trading band.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $3.08 | $3.13 | $4.02 | 0% | Neutral | |
| $2.93 | $3.77 | $5.17 | +20% | Bullish | |
| $3.50 | $4.65 | $6.66 | +49% | Bullish | |
| $3.48 | $4.76 | $7.04 | +52% | Bullish | |
| $3.71 | $5.21 | $7.92 | +66% | Bullish | |
| $3.66 | $5.26 | $8.19 | +68% | Bullish | |
| $3.42 | $5.03 | $8.00 | +61% | Bullish | |
| $3.77 | $5.64 | $9.16 | +80% | Bullish | |
| $4.56 | $6.96 | $11.51 | +123% | Bullish | |
| $5.15 | $8.01 | $13.47 | +156% | Bullish | |
| $5.67 | $9.62 | $17.33 | +207% | Bullish | |
| $9.17 | $18.14 | $36.16 | +479% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| May 2026 | $3.08 | $3.13 | $3.66 | +0.00% |
| June 2026 | $2.54 | $3.00 | $3.64 | -4.10% |
| July 2026 | $2.56 | $3.05 | $3.76 | +1.72% |
| August 2026 | $2.50 | $3.01 | $3.75 | -1.46% |
| September 2026 | $2.39 | $2.89 | $3.63 | -4.11% |
| October 2026 | $2.43 | $2.96 | $3.76 | +2.66% |
| November 2026 | $2.56 | $3.13 | $4.00 | +5.55% |
| December 2026 | $2.54 | $3.12 | $4.02 | -0.24% |
Click any year to see its month-by-month SRTS forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
In 2026, SRTS is projected to trade between $3.08 and $4.02, averaging $3.13 — a potential gain of 0% from today's $3.13. A consolidation phase looks the most probable path here.
Sensus Healthcare, Inc.'s 2027 outlook centres on $3.77, within a $2.93 to $5.17 range. That is up +20% on the projected 2026 average. That marks a +20% change versus current levels. Momentum favours further upside here.
By 2028, SRTS could reach as high as $6.66, with a base case around $4.65 and support toward $3.50 — roughly +49% from $3.13. Buyers look set to stay in control over this stretch.
Expect SRTS to range from $3.48 to $7.04 through 2029. The $4.76 average target implies a +52% move from current prices. That is up +2% on the projected 2028 average. Momentum favours further upside here.
The SRTS price prediction for 2030 points to an average of $5.21 (low $3.71, high $7.92) — a potential gain of +66% on today's $3.13. Buyers look set to stay in control over this stretch.
In 2031, SRTS is projected to trade between $3.66 and $8.19, averaging $5.26 — a potential gain of +68% from today's $3.13. That is up +1% on the projected 2030 average. Momentum favours further upside here.
Sensus Healthcare, Inc.'s 2032 outlook centres on $5.03, within a $3.42 to $8.00 range. That is -4% versus the projected 2031 average. That marks a +61% change versus current levels. Buyers look set to stay in control over this stretch.
By 2033, SRTS could reach as high as $9.16, with a base case around $5.64 and support toward $3.77 — roughly +80% from $3.13. Momentum favours further upside here.
Expect SRTS to range from $4.56 to $11.51 through 2034. The $6.96 average target implies a +123% move from current prices. That is up +23% on the projected 2033 average. Buyers look set to stay in control over this stretch.
The SRTS price prediction for 2035 points to an average of $8.01 (low $5.15, high $13.47) — a potential gain of +156% on today's $3.13. Momentum favours further upside here.
In 2040, SRTS is projected to trade between $5.67 and $17.33, averaging $9.62 — a potential gain of +207% from today's $3.13. That is up +20% on the projected 2035 average. Buyers look set to stay in control over this stretch.
Sensus Healthcare, Inc.'s 2050 outlook centres on $18.14, within a $9.17 to $36.16 range. That is up +89% on the projected 2040 average. That marks a +479% change versus current levels. Momentum favours further upside here.
Investing $1,000 in SRTS today (≈ 319.488818 SRTS) could be worth
$5,794.51
+$4,794.51 (+479%) by 2050 · US Dollar
Based on the average projected SRTS price of $18.14 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in SRTSwould be worth at today's price.
$1,000 invested in SRTS on May 27, 2025 (≈ 207.468872 SRTS) would be worth
$649.38
-$350.62 (-35.1%) today · 0.65× · US Dollar
Based on a SRTS entry price of $4.82 vs. today's $3.13.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $3.32 | $942.77 | -5.7% |
| 1 month ago | $3.96 | $790.4 | -21.0% |
| 3 months ago | $4.02 | $778.61 | -22.1% |
| 6 months ago | $4.19 | $747.02 | -25.3% |
| 1 year ago | $4.82 | $649.38 | -35.1% |
| All time (5.0y) ago | $3.51 | $891.74 | -10.8% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our SRTS forecast.
Our base-case forecast reaches $6.30 around 2034.
Implied market cap at $6.30: $103.71M
The multi-year forecast shows a bullish trajectory after 2027. For 2026 the min is $3.08, avg $3.19 and max $4.07 with 0% ROI and neutral sentiment. In 2027, min $2.93, avg $3.79 and max $5.25 with 18.9% ROI and neutral sentiment.
Starting 2028, the outlook turns more clearly bullish, with 2028 min $3.50, avg $4.70 and max $6.80 (47.3% ROI); 2029 min $3.43, avg $4.75 and max $7.11 (48.9% ROI); 2030 min $3.68, avg $5.23 and max $8.06 (64% ROI). The bullish trend continues through 2031–2035, 2040 and 2050, with 2031 avg $5.22 (63.7% ROI), 2032 avg $4.87 (52.6% ROI), 2033 avg $5.55 (73.9% ROI), 2034 avg $6.84 (114.3% ROI), 2035 avg $7.80 (144.6% ROI), 2040 avg $9.21 (188.9% ROI), and 2050 avg $17.31 (442.6% ROI) with a bullish sentiment across the later years.
Tap a question to reveal the answer.
For 2030, the forecast shows an average price of $5.23 with a min of $3.68 and a max of $8.06, and an expected ROI of 64% with a bullish sentiment.
The outlook turns bullish from 2028 onward, with rising average prices and higher ROIs through 2050 (e.g., 2040 ROI of 188.9% and 2050 ROI of 442.6%). Earlier years show neutral sentiment, and the 2026-2027 period has modest ROIs of 0% and 18.9% respectively.
Yes. The forecasted maximum prices include 2034 with a max of $11.48 and 2033 with a max of $9.15, indicating the possibility of reaching or exceeding $10 in the mid-term horizon.
The current price is $3.19 and the market cap is $52.51M.
The path shows a long-term bullish trajectory, with 2028 avg $4.70, 2030 avg $5.23, 2040 avg $9.21, and 2050 avg $17.31; max values rise to $6.80 (2028), $8.06 (2030), $16.93 (2040), and $35.29 (2050), reflecting a substantial upside by 2050 and a 442.6% ROI at the max in 2050.
Sensus Healthcare, Inc. Community Discussion
0Share your Sensus Healthcare, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.